GSK plc

London, X0 · CIK 1131399 · 13F filing filed 2026-08-13

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

Legal entityGSK PLC (GB)

$602.2m reported value +0.5% vs Q1 2026

13positions

97.5%in top 10

0 new 0 added 0 reduced 0 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#	Security	Ticker	Shares	Value	% of portfolio	Change
1	CRISPR THERAPEUTICS AG NAMEN AKT CRSP	CRSP	3,220,627	$175.7m29.17%	29.17%	Unchanged
2	WAVE LIFE SCIENCES LTD SHS 96663EUR	96663EUR	18,245,691	$106.0m17.60%	17.60%	Unchanged
3	VIR BIOTECHNOLOGY INC COM VIR	VIR	8,550,954	$87.1m14.47%	14.47%	Unchanged
4	BIONTECH SE SPONSORED ADS BNTX	BNTX	889,824	$82.8m13.75%	13.75%	Unchanged
5	IDEAYA BIOSCIENCES INC COM IDYA	IDYA	1,333,333	$49.7m8.25%	8.25%	Unchanged
6	CYTOKINETICS INC COM NEW CYTK	CYTK	340,434	$29.0m4.82%	4.82%	Unchanged
7	LYELL IMMUNOPHARMA INC COM NEW LYEL	LYEL	1,512,659	$21.3m3.53%	3.53%	Unchanged
8	SPERO THERAPEUTICS INC COM SPRO	SPRO	9,190,606	$20.3m3.37%	3.37%	Unchanged
9	NKARTA INC COM NKTX	NKTX	3,150,732	$8.9m1.48%	1.48%	Unchanged
10	FULCRUM THERAPEUTICS INC COM FULC	FULC	1,785,714	$6.5m1.09%	1.09%	Unchanged
11	BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC	BCYC	1,529,561	$6.5m1.08%	1.08%	Unchanged
12	CVRX INC COM CVRX	CVRX	1,007,583	$5.2m0.86%	0.86%	Unchanged
13	REGENXBIO INC COM RGNX	RGNX	271,456	$3.3m0.54%	0.54%	Unchanged

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

Company	Ticker	Stake	Change	Schedule	Last filed
SPERO THERAPEUTICS INC SPRO · 13D · filed 2025-03-28	SPRO	16.4%≈ $20.3m		13D	2025-03-28